BALAXI PHARMA LTD

On August 6, 2026, Balaxi Pharmaceuticals Limited submitted an investor presentation detailing the financial results for the quarter ended June 30, 2026. The presentation highlighted a 14% year-over-year increase in consolidated revenue to ₹80.68 crore, with a gross profit margin improvement of 241 basis points to 46.5%. Profit after tax rose significantly to ₹1.29 crore from ₹0.29 crore in the previous year. Management noted the successful commencement of commercial production at their first pharmaceutical formulation facility in Hyderabad, which has received approvals for 31 products. The company reported a total of 980 registered products across key markets and emphasized ongoing efforts in institutional business expansion and backward integration. The document also outlined strategic goals for market presence in Africa and Latin America, alongside a focus on operational efficiency and sustainable value creation.

Management emphasized strong revenue growth and improved profitability.